Omeros CORP

Omeros Corporation announced the appointment of Joseph Schocken to its Board of Directors, effective August 12, 2026, expanding the board to nine members.

Omeros Corporation announced robust second quarter 2026 financial results, highlighted by a significant increase in YARTEMLEA revenue and improved operational cash flow.

Omeros Corporation announced the completion of a $14.5 million repurchase of its 9.50% Convertible Senior Notes due 2029, bringing the total retired to $30.5 million.

Omeros Corporation announced the expected completion of a $16.0 million repurchase of its 9.50% Convertible Senior Notes due 2029 and entered into agreements for an additional repurchase of up to $14.5 million.

Omeros Corporation announced the results of its 2026 Annual Meeting, where shareholders re-elected three directors and approved the company's executive compensation and incentive plans.

Omeros Corporation announced agreements to repurchase up to $16.0 million in aggregate principal amount of its 9.50% Convertible Senior Notes due 2029.

Omeros Corporation's Q2 2026 Form 10-Q highlights robust YARTEMLEA sales growth and positive pipeline advancements, alongside a significant repurchase of convertible notes.

Omeros Corporation announces first quarter 2026 financial results, highlighting initial product sales for YARTEMLEA and significant gains from financial instrument revaluation.

Omeros Corporation reports Q3 2025 results, highlighting a significant deal with Novo Nordisk for zaltenibart and an extended PDUFA date for narsoplimab.

Omeros Corporation reported a net loss of $58.9 million for the first six months of 2025, while actively restructuring debt and advancing its clinical pipeline, including a PDUFA extension for narsoplimab.

Omeros Corporation's Q1 2025 results reveal a net loss and going concern uncertainty, despite efforts to restructure debt and advance its clinical programs.

Omeros Corporation's Q3 2024 results reveal ongoing financial challenges and strategic efforts to advance its clinical programs, particularly narsoplimab.

Omeros Corporation files an amendment to its 2024 annual report to include information previously omitted regarding directors, executive compensation, security ownership, related transactions, and accounting fees.

Omeros Corporation's 10-K filing reveals substantial doubt about its ability to continue as a going concern, even as it resubmits its BLA for narsoplimab in TA-TMA and advances other clinical programs.

Omeros Corporation has entered into a license agreement with Asubio Pharma, amended a license agreement with Daiichi Sankyo, and a royalty agreement with DRI Healthcare Acquisitions LP, expanding its therapeutic pipeline and securing funding.

David J. Borges, VP, Finance & CAO of Omeros Corp, sold 5,000 shares of common stock on August 13, 2026 for $16.95 per share.

Gregory A Demopulos, Chairman, CEO & President and a Director of Omeros Corp, received 1,000,000 shares of common stock on July 22, 2026.

Peter B Cancelmo, VP, General Counsel of Omeros Corp, received 105,000 shares of common stock on July 22, 2026.

David J. Borges, VP, Finance & CAO of Omeros Corp, received 105,000 shares of common stock on July 22, 2026.

Director Thomas J. Cable exercised 7,500 stock options and sold the resulting shares under a pre-established Rule 10b5-1 plan.

Omeros Corp's Chairman, CEO, and President, Gregory A. Demopulos, MD, exercised 400,000 stock options and settled associated tax liabilities through a net share settlement on February 18, 2026.

Omeros Corporation announces its 2026 Annual Meeting of Shareholders, to be held virtually on June 18, 2026, with key proposals including director elections and executive compensation.

Omeros Corporation announced its 2025 Annual Meeting of Shareholders, detailing significant 2024 advancements in its clinical pipeline, including narsoplimab and zaltenibart, alongside strategic financial maneuvers to strengthen its balance sheet.

Omeros Corporation will hold its 2024 Annual Meeting of Shareholders virtually on June 6, 2024, to vote on director elections, executive compensation, and the ratification of its accounting firm.

Ingalls & Snyder LLC has reported a beneficial ownership of 3,466,268 shares of Omeros Corp common stock, representing 4.8% of the class, as of December 31, 2025.

The Vanguard Group filed an amended Schedule 13G for Omeros Corp, reporting zero beneficial ownership following an internal realignment.

The Vanguard Group has reported a 5.66% beneficial ownership stake in Omeros Corp, totaling 4,013,315 common shares.

The Vanguard Group has filed an amendment to its Schedule 13G, reporting a 4.91% beneficial ownership stake in Omeros Corp as of September 30, 2025.

Investment firm Ingalls & Snyder LLC has disclosed a 7.2% beneficial ownership stake in Omeros Corp, holding 4,161,315 shares as of December 31, 2024.